Similar articles

• Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.

  Taccetti G, Campana S, Festini F, Mascherini M, Döring G. Taccetti G, et al. Eur Respir J. 2005 Sep;26(3):458-61. doi: 10.1183/09031936.05.00009605. Eur Respir J. 2005. PMID: 16135728
• The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis.

  Amin R, Lam M, Dupuis A, Ratjen F. Amin R, et al. Pediatr Pulmonol. 2011 Jun;46(6):554-8. doi: 10.1002/ppul.21417. Epub 2011 Feb 18. Pediatr Pulmonol. 2011. PMID: 21337727
• Changes in lung function in young cystic fibrosis patients between two courses of intravenous antibiotics against Pseudomonas aeruginosa.

  Béghin L, Michaud L, Loeuille GA, Wizla-Derambure N, Sayah H, Sardet A, Thumerelle C, Deschildre A, Turck D, Gottrand F. Béghin L, et al. Pediatr Pulmonol. 2009 May;44(5):464-71. doi: 10.1002/ppul.21017. Pediatr Pulmonol. 2009. PMID: 19360849
• Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.

  Assael BM. Assael BM. Expert Rev Anti Infect Ther. 2011 Nov;9(11):967-73. doi: 10.1586/eri.11.131. Expert Rev Anti Infect Ther. 2011. PMID: 22029514 Review.
• Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.

  Stockmann C, Hillyard B, Ampofo K, Spigarelli MG, Sherwin CM. Stockmann C, et al. Expert Rev Respir Med. 2015 Feb;9(1):13-22. doi: 10.1586/17476348.2015.986469. Epub 2014 Nov 24. Expert Rev Respir Med. 2015. PMID: 25417708 Review.